Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism.

@article{Furlan1999IntraarterialPF,
  title={Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism.},
  author={Anthony J. Furlan and Randall T. Higashida and Lawrence R. Wechsler and Michael Gent and Howard A. Rowley and Carlos S. Kase and Michael S. Pessin and A Ahuja and Fred Callahan and Wayne M. Clark and Frank L. Silver and Francisca Rivera},
  journal={JAMA},
  year={1999},
  volume={282 21},
  pages={
          2003-11
        }
}
CONTEXT Intravenous tissue-type plasminogen activator can be beneficial to some patients when given within 3 hours of stroke onset, but many patients present later after stroke onset and alternative treatments are needed. OBJECTIVE To determine the clinical efficacy and safety of intra-arterial (IA) recombinant prourokinase (r-proUK) in patients with acute stroke of less than 6 hours' duration caused by middle cerebral artery (MCA) occlusion. DESIGN PROACT II (Prolyse in Acute Cerebral… 
Thromobolysis for acute ischemic stroke: is intra-arterial better than intravenous? A treatment effects model.
  • W. Powers
  • Medicine
    Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association
  • 2012
New insights on thrombolytic treatment of acute ischemic stroke
In 1995, a two-part randomized trial showed the efficacy of intravenous tissue plasminogen activator (tPA) when given within 3 hours of onset of symptoms of acute ischemic stroke. Two subsequent
Cerebral hemorrhage after intra-arterial thrombolysis for ischemic stroke
TLDR
Symptomatic ICH after IA thrombolysis with r-proUK for acute ischemic stroke occurs early after treatment and has high mortality, and the risk of symptomatic I CH may be increased in patients with a blood glucose >200 mg/dL at stroke onset.
Randomized Trial of Intraarterial Infusion of Urokinase Within 6 Hours of Middle Cerebral Artery Stroke: The Middle Cerebral Artery Embolism Local Fibrinolytic Intervention Trial (MELT) Japan
TLDR
The trial was aborted prematurely and the primary end point did not reach statistical significance, but secondary analyses suggested that intraarterial fibrinolysis has the potential to increase the likelihood of excellent functional outcome.
Is Intra-Arterial Thrombolysis Safe After Full-Dose Intravenous Recombinant Tissue Plasminogen Activator for Acute Ischemic Stroke?
TLDR
IAT therapy after full-dose IV rt-PA in patients with persisting occlusion and/or lack of clinical improvement appears safe compared with IV rT-PA alone or low-dose intravenous recombinant tissue plasminogen activator followed by IAT.
Intra-arterial Thrombolysis for Acute Ischemic Stroke: Preliminary Experience with Platelet Glycoprotein IIb/IIIa Inhibitors as Adjunctive Therapy
TLDR
IIb/IIIa inhibitors are an alternative for achieving recanalization in patients with large-vessel occlusion and acute ischemic stroke syndrome as part of an escalating protocol that includes pharmacological and mechanical thrombolysis, and may improve clinical outcomes.
Intra-Arterial Adjunctive Medications for Acute Ischemic Stroke During Mechanical Thrombectomy
TLDR
In acute ischemic stroke with large vessel occlusion, the use of IAM together with MT may achieve better functional outcomes and lower mortality rates.
Endovascular (Intraarterial) Treatment of Acute Ischemic Stroke: Efficacy Not Supported by Clinical Trials
  • W. Powers
  • Medicine, Psychology
    Southern medical journal
  • 2014
TLDR
If there is a role for endovascular treatment of acute ischemic stroke, it is for patients who can be treated under 4.5 hours but who are ineligible for IV tPA because of increased hemorrhage risk from systemic thrombolytic drug effects, although this remains unproven.
Intra-arterial thrombolysis for acute ischemic stroke.
  • T. Jovin, J. Gebel, L. Wechsler
  • Medicine
    Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association
  • 2002
TLDR
Although intra-arterial thrombolysis appears to be an effective and relatively safe form of therapy for certain patients with acute ischemic stroke, better outcomes and fewer side effects than currently reported are to be desired.
Intra-arterial Third-generation Recombinant Tissue Plasminogen Activator (Reteplase) for Acute Ischemic Stroke
TLDR
In this study, intra-arterially administered reteplase in doses up to 8 U with or without angioplasty resulted in a high rate of recanalization, and should be considered in treating patients considered poor candidates for intravenous thrombolysis.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 40 REFERENCES
PROACT: a phase II randomized trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke. PROACT Investigators. Prolyse in Acute Cerebral Thromboembolism.
TLDR
Intra-arterial local rpro-UK infusion was associated with superior recanalization in acute thrombotic/ thromboembolic stroke compared with placebo, and this study suggests that recenalization is enhanced with r Pro-UK and heparin.
Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS)
TLDR
Intravenous thrombolysis in acute ischemic stroke is effective in improving some functional measures and neurologic outcome in a defined subgroup of stroke patients with moderate to severe neurologic deficit and without extended infarct signs on the initial CT scan, however, the identification of this subgroup is difficult.
Neuroradiologic evaluation of patients with acute stroke treated with recombinant tissue plasminogen activator. The rt-PA Acute Stroke Study Group.
TLDR
Emergency cerebral angiography adds important information about the nature and extent of the arterial occlusions, and the recanalization efficacy of fibrinolytic therapy for patients with acute stroke.
Intra-arterial pro-urokinase in ischemic stroke.
TLDR
The first randomized, double-blind, controlled trial of intra-arterial pro-urokinase (pro-UK) in ischemic stroke (PROACT) successfully completed, and it is curious that intravenous heparin was given concomitantly with pro-UK in the treatment group or given alone in the placebo group.
Recombinant tissue plasminogen activator in acute thrombotic and embolic stroke
TLDR
It is indicated that site of occlusion, time to recanalization, and time to treatment are important variables in acute stroke intervention with this agent.
Local intra-arterial fibrinolytic therapy in acute carotid territory stroke. A pilot study.
TLDR
It is concluded that local intra-arterial fibrinolytic therapy may lead to cerebral arterial recanalization in acute carotid territory thrombotic stroke.
Thrombolytic therapy with streptokinase in acute ischemic stroke.
TLDR
In patients with acute ischemic stroke, treatment with strePTokinase resulted in an increase in mortality, and the routine use of streptokinase cannot be recommended in acute isChemic stroke.
Local intra-arterial thrombolysis in acute ischemic stroke.
TLDR
LIT was most efficacious in patients with MCA and BA occlusions when the initial NIHSS score was less than 20 and when treated within 4 hours and is of limited value in Patients with distal ICA occlusion.
Streptokinase for acute ischemic stroke with relationship to time of administration: Australian Streptokinase (ASK) Trial Study Group.
TLDR
The administration of streptokinase within 4 hours of acute ischemic stroke increased morbidity and mortality at 3 months and treatment within 3 hours of stroke was safer and associated with significantly better outcomes than later treatment.
...
1
2
3
4
...